Overview

Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a study to assess the safety, tolerability, and PK of oral TPOXX 600 mg when administered BID for 28 days in adult subjects.
Phase:
Phase 3
Details
Lead Sponsor:
SIGA Technologies
Collaborators:
Biomedical Advanced Research and Development Authority
Medical CBRN Defense Consortium (MCDC)
United States Department of Defense